Research partners hope to develop novel antibody-drug conjugates
Drug Discovery World
JANUARY 3, 2023
Under the terms of the agreement, Mersana will develop novel ADC product candidates against up to two targets utilising its Immunosynthen platform to conjugate proprietary antibodies from Merck KGaA, Darmstadt, Germany. . Mersana will receive an upfront payment of $30 million.
Let's personalize your content